JP2020500016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500016A5 JP2020500016A5 JP2019523779A JP2019523779A JP2020500016A5 JP 2020500016 A5 JP2020500016 A5 JP 2020500016A5 JP 2019523779 A JP2019523779 A JP 2019523779A JP 2019523779 A JP2019523779 A JP 2019523779A JP 2020500016 A5 JP2020500016 A5 JP 2020500016A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cancer
- human ctla
- activable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022036450A JP7472183B2 (ja) | 2016-11-03 | 2022-03-09 | 活性化可能な抗ｃｔｌａ－４抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417212P | 2016-11-03 | 2016-11-03 | |
| US62/417,212 | 2016-11-03 | ||
| PCT/US2017/059740 WO2018085555A1 (en) | 2016-11-03 | 2017-11-02 | Activatable anti-ctla-4 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036450A Division JP7472183B2 (ja) | 2016-11-03 | 2022-03-09 | 活性化可能な抗ｃｔｌａ－４抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500016A JP2020500016A (ja) | 2020-01-09 |
| JP2020500016A5 true JP2020500016A5 (enExample) | 2020-12-10 |
| JP7039582B2 JP7039582B2 (ja) | 2022-03-22 |
Family
ID=61132883
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523779A Active JP7039582B2 (ja) | 2016-11-03 | 2017-11-02 | 活性化可能な抗ｃｔｌａ－４抗体およびその使用 |
| JP2022036450A Active JP7472183B2 (ja) | 2016-11-03 | 2022-03-09 | 活性化可能な抗ｃｔｌａ－４抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022036450A Active JP7472183B2 (ja) | 2016-11-03 | 2022-03-09 | 活性化可能な抗ｃｔｌａ－４抗体およびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11117968B2 (enExample) |
| EP (1) | EP3535300B1 (enExample) |
| JP (2) | JP7039582B2 (enExample) |
| KR (2) | KR102584340B1 (enExample) |
| CN (1) | CN110072890B (enExample) |
| AR (1) | AR110678A1 (enExample) |
| AU (1) | AU2017355446A1 (enExample) |
| BR (1) | BR112019008223A2 (enExample) |
| CA (1) | CA3042679A1 (enExample) |
| CL (1) | CL2019001226A1 (enExample) |
| CO (1) | CO2019004469A2 (enExample) |
| EA (1) | EA201990875A1 (enExample) |
| ES (1) | ES3053667T3 (enExample) |
| IL (1) | IL265625A (enExample) |
| MX (1) | MX2019004775A (enExample) |
| MY (1) | MY200695A (enExample) |
| PE (1) | PE20191131A1 (enExample) |
| SG (1) | SG11201902857SA (enExample) |
| TW (2) | TW202334213A (enExample) |
| WO (1) | WO2018085555A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX379106B (es) | 2013-09-25 | 2025-03-11 | Cytomx Therapeutics Inc | Substratos de metaloproteinasas de matriz y otras porciones escindibles y métodos para usar los mismos. |
| IL317045A (en) | 2014-01-31 | 2025-01-01 | Cytomx Therapeutics Inc | Polypeptide substrates activating tryptase and U-plasminogen and other cleavable groups, compositions containing them and uses thereof |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| WO2018085555A1 (en) | 2016-11-03 | 2018-05-11 | Bristol-Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
| JP7001615B2 (ja) | 2016-11-28 | 2022-02-03 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| US12060654B2 (en) | 2016-11-28 | 2024-08-13 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule having adjustable ligand binding activity |
| KR102522693B1 (ko) | 2017-05-19 | 2023-04-17 | 우시 바이올로직스 (상하이) 컴퍼니 리미티드 | 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체 |
| EP3706803A4 (en) | 2017-11-08 | 2021-08-04 | Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. | CONJUGATES BASED ON A BIOMOLECULE AND THEIR USE |
| SG11202004627WA (en) | 2017-11-28 | 2020-06-29 | Chugai Pharmaceutical Co Ltd | Ligand-binding molecule having adjustable ligand-binding activity |
| JP7482630B2 (ja) * | 2017-11-28 | 2024-05-14 | 中外製薬株式会社 | 抗原結合ドメインおよび運搬部分を含むポリペプチド |
| JP2021518603A (ja) | 2018-03-20 | 2021-08-02 | シートムエックス セラピューティクス，インコーポレイテッド | 哺乳動物対象における活性化可能抗体種の定量薬理学モデリングのためのシステムおよび方法 |
| MX2020012252A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
| MX2020012251A (es) | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina-2 activables y metodos de uso de los mismos. |
| WO2019230867A1 (en) | 2018-05-30 | 2019-12-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide comprising aggrecan binding domain and carrying moiety |
| KR20210141447A (ko) | 2018-12-26 | 2021-11-23 | 실리오 디벨럽먼트, 인크. | 항-ctla4 항체 및 이의 사용 방법 |
| MA55316A (fr) | 2019-03-13 | 2022-01-19 | Merck Sharp & Dohme | Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1 |
| JP7720785B2 (ja) | 2019-04-18 | 2025-08-08 | ブリストル－マイヤーズ スクイブ カンパニー | 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| CN110498856B (zh) * | 2019-09-17 | 2020-08-11 | 浙江玉安康瑞生物科技有限公司 | 一种ctla-4单克隆抗体5h7及其用于抗肿瘤的用途 |
| MX2022005474A (es) | 2019-11-08 | 2022-06-02 | Bristol Myers Squibb Co | Tratamiento de melanoma con antagonistas del gen 3 de activacion de linfocitos (lag-3). |
| JP2023510108A (ja) | 2019-12-19 | 2023-03-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｄｇｋ阻害剤およびチェックポイントアンタゴニストの組み合わせ |
| AU2021208642B2 (en) * | 2020-01-17 | 2025-06-05 | Immunelogic Therapeutics, Inc. | Pro-antibody that reduces off-target toxicity |
| PH12022552632A1 (en) * | 2020-04-01 | 2023-01-04 | Xilio Dev Inc | Masked il-12 cytokines and their cleavage products |
| IL296634A (en) | 2020-04-09 | 2022-11-01 | Cytomx Therapeutics Inc | Preparations containing activatable antibodies |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| CN115803343A (zh) * | 2020-05-26 | 2023-03-14 | 百奥泰生物制药股份有限公司 | 多特异性抗体及其应用 |
| CA3187754A1 (en) | 2020-08-11 | 2022-02-17 | David Campbell | Cleavable linker compositions and methods |
| MX2023006817A (es) | 2020-12-09 | 2023-08-14 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras. |
| CA3209364A1 (en) * | 2021-03-01 | 2022-09-09 | Jennifer O'neil | Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer |
| JP2024523443A (ja) | 2021-06-21 | 2024-06-28 | ブリストル－マイヤーズ スクイブ カンパニー | 高濃度凍結乾燥生物製剤の再構成時間を減少させるためのスクロース、マンニトールおよびグリシンの使用 |
| WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
| EP4496816A1 (en) | 2022-03-23 | 2025-01-29 | CytomX Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
| JP2025512798A (ja) | 2022-03-25 | 2025-04-22 | サイトムエックス セラピューティクス，インク． | 活性化可能な二重アンカー型マスク化分子及びその使用方法 |
| WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
| US20250215110A1 (en) | 2022-04-01 | 2025-07-03 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
| WO2023196987A1 (en) | 2022-04-07 | 2023-10-12 | Bristol-Myers Squibb Company | Methods of treating tumor |
| EP4565250A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| EP4565261A1 (en) | 2022-08-01 | 2025-06-11 | CytomX Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| TW202424184A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| WO2024031032A1 (en) | 2022-08-05 | 2024-02-08 | Bristol-Myers Squibb Company | Anti-ctla-4 antibodies for treatment of kras mutant cancers |
| CN120019078A (zh) * | 2022-09-02 | 2025-05-16 | 西奇利德股份有限公司 | 抗ctla-4单克隆抗体及其用途 |
| WO2024216170A2 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| WO2024216146A1 (en) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Masking polypeptides, activatable cytokine constructs, and related compositions and methods |
| CN120958015A (zh) | 2023-04-12 | 2025-11-14 | 西托姆克斯治疗公司 | 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法 |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| US20250361320A1 (en) | 2024-02-27 | 2025-11-27 | Bristol-Myers Squibb Company | Anti-ceacam5 antibodies and uses thereof |
| EP4658320A1 (en) | 2024-02-27 | 2025-12-10 | Bristol-Myers Squibb Company | Anti-ceacam5 antibody drug conjugates |
| WO2025240659A2 (en) | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026020161A1 (en) | 2024-07-19 | 2026-01-22 | Cytomx Therapeutics, Inc. | Activatable il-12 constructs and related compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| NZ258392A (en) | 1992-11-13 | 1997-09-22 | Idec Pharma Corp | Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| CN1371416B (zh) * | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001091798A2 (en) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Tumor activated prodrug compounds |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| AU9399501A (en) | 2000-10-09 | 2002-04-22 | Isis Innovation | Therapeutic antibodies |
| BR0213761A (pt) | 2001-10-25 | 2005-04-12 | Genentech Inc | Composições, preparação farmacêutica, artigo industrializado, método de tratamento de mamìferos, célula hospedeira, método para a produção de uma glicoproteìna e uso da composição |
| WO2003085107A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cells with modified genome |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| WO2004021861A2 (en) | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| KR101291640B1 (ko) | 2005-02-18 | 2013-08-05 | 메다렉스, 엘.엘.시. | 푸코실 잔기가 결핍된 전립선 특이적 막 항원(ｐｓｍａ)에대한 단클론성 항체 |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| EP1919931A4 (en) | 2005-08-31 | 2010-01-20 | Univ California | CELLULAR PEPTIDE SEQUENCE LIBRARIES (CLIPS) AND METHOD OF USE THEREOF |
| WO2007084672A2 (en) | 2006-01-17 | 2007-07-26 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
| US20090220529A1 (en) | 2006-03-10 | 2009-09-03 | Diatos, S.A. | Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker |
| AU2007308983B2 (en) | 2006-10-24 | 2012-12-06 | Emergent Product Development Seattle, Llc | A method for increasing antibody-dependent cytotoxicity with castanospermine |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| WO2009014726A1 (en) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| CA2975228C (en) | 2008-05-02 | 2020-07-21 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| WO2012112687A1 (en) * | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Methods of preparation of conjugates |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| US8852599B2 (en) * | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| WO2013163631A2 (en) | 2012-04-27 | 2013-10-31 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| CA3213528A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN-BINDING PROTEINS FOR BINDING PD-L1 |
| US9127053B2 (en) | 2012-06-22 | 2015-09-08 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| PL2925350T3 (pl) * | 2012-12-03 | 2019-07-31 | Bristol-Myers Squibb Company | Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| EA035322B1 (ru) * | 2013-05-28 | 2020-05-28 | ДиЭсБи-ЮЭсЭй ЛЛК | Антитело с "запирающими" свойствами для инактивации лекарства белкового происхождения |
| CA2913977C (en) | 2013-05-31 | 2022-11-29 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| CA3078121A1 (en) | 2013-09-13 | 2015-03-19 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| EP3059319A4 (en) | 2013-10-07 | 2017-04-26 | Prestige Biopharma Pte. Ltd. | Bicistronic expression vector for antibody expression and method for producing antibody using same |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2016004383A1 (en) | 2014-07-03 | 2016-01-07 | City Of Hope | Tumor-selective ctla-4 antagonists |
| EP3172235A2 (en) * | 2014-07-25 | 2017-05-31 | Cytomx Therapeutics Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP3237446B1 (en) | 2014-12-22 | 2021-05-05 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| EP3733696A1 (en) * | 2015-01-13 | 2020-11-04 | City of Hope | Ctla4-binding protein peptide-linker masks |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| EP3268392A2 (en) * | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| SI3334763T1 (sl) | 2015-08-11 | 2025-01-31 | WuXi Biologics Ireland Limited | Nova protitelesa proti pd-1 |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| HK1257840A1 (zh) | 2015-09-01 | 2019-11-01 | Agenus Inc. | 抗-pd-1抗体及其使用方法 |
| MA44082A (fr) | 2015-12-14 | 2018-10-24 | Macrogenics Inc | Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation |
| WO2017123557A1 (en) | 2016-01-11 | 2017-07-20 | Armo Biosciences, Inc. | Interleukin-10 in production of antigen-specific cd8+ t cells and methods of use of same |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2018085555A1 (en) | 2016-11-03 | 2018-05-11 | Bristol-Myers Squibb Company | Activatable anti-ctla-4 antibodies and uses thereof |
| EP3625253A4 (en) | 2017-05-16 | 2021-03-24 | Scalmibio, Inc. | ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE |
| KR20200040819A (ko) | 2017-08-16 | 2020-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | 항체를 표적화하기 위한 항 ctla-4 프로바디 치료제 |
-
2017
- 2017-11-02 WO PCT/US2017/059740 patent/WO2018085555A1/en not_active Ceased
- 2017-11-02 EP EP17837917.8A patent/EP3535300B1/en active Active
- 2017-11-02 KR KR1020197015448A patent/KR102584340B1/ko active Active
- 2017-11-02 CA CA3042679A patent/CA3042679A1/en active Pending
- 2017-11-02 KR KR1020237032965A patent/KR102814027B1/ko active Active
- 2017-11-02 PE PE2019000902A patent/PE20191131A1/es unknown
- 2017-11-02 BR BR112019008223-9A patent/BR112019008223A2/pt not_active IP Right Cessation
- 2017-11-02 AU AU2017355446A patent/AU2017355446A1/en not_active Abandoned
- 2017-11-02 SG SG11201902857SA patent/SG11201902857SA/en unknown
- 2017-11-02 ES ES17837917T patent/ES3053667T3/es active Active
- 2017-11-02 CN CN201780066620.7A patent/CN110072890B/zh active Active
- 2017-11-02 EA EA201990875A patent/EA201990875A1/ru unknown
- 2017-11-02 MY MYPI2019002439A patent/MY200695A/en unknown
- 2017-11-02 JP JP2019523779A patent/JP7039582B2/ja active Active
- 2017-11-02 MX MX2019004775A patent/MX2019004775A/es unknown
- 2017-11-02 US US16/347,522 patent/US11117968B2/en active Active
- 2017-11-03 TW TW111141621A patent/TW202334213A/zh unknown
- 2017-11-03 AR ARP170103060A patent/AR110678A1/es unknown
- 2017-11-03 TW TW106138139A patent/TWI784983B/zh not_active IP Right Cessation
-
2019
- 2019-03-26 IL IL265625A patent/IL265625A/en unknown
- 2019-04-30 CO CONC2019/0004469A patent/CO2019004469A2/es unknown
- 2019-05-03 CL CL2019001226A patent/CL2019001226A1/es unknown
-
2021
- 2021-08-11 US US17/399,729 patent/US12441799B2/en active Active
-
2022
- 2022-03-09 JP JP2022036450A patent/JP7472183B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500016A5 (enExample) | ||
| JP2022065174A5 (enExample) | ||
| JP2022046569A5 (enExample) | ||
| RU2020115713A (ru) | Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения | |
| JP2022064924A5 (enExample) | ||
| JP2020536109A5 (enExample) | ||
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| JP2020513809A5 (enExample) | ||
| RU2016106115A (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения | |
| JP2020500538A5 (enExample) | ||
| ME02807B (me) | HUMANI ANTIGEN-VEZUJUĆI PROTEINI KOJI SE VEZUJU ZA BETA-KLOTHO, FGF RECEPTORE l NJIHOVE KOMPLEKSE | |
| JP2019110906A5 (enExample) | ||
| JP2018520092A5 (enExample) | ||
| JP2020514310A5 (enExample) | ||
| JP2020537649A5 (enExample) | ||
| JP2020516240A5 (enExample) | ||
| JP2009505676A5 (enExample) | ||
| JP2018520091A5 (enExample) | ||
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| JP2016525551A5 (enExample) | ||
| RU2010123888A (ru) | Axl-антитела | |
| RU2013136172A (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| HRP20200721T1 (hr) | Aktivirajuća anti-cd166 antitijela i postupci njihove uporabe | |
| JP2017506217A5 (enExample) | ||
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |